Winner of the Actuarial Award in Asia, 2013

Document PDF

SCOR a obtenu l’autorisation des Lloyd’s, du Financial Conduct Authority et du Prudential Regulatory Authority au Royaume-Uni pour la création d’un opérateur (Managing Agent) aux Lloyd’s.

En 2013, une neurologie conquérante et innovante voit le jour : la génétique, la biotechnologie, l’imagerie médicale, la neurochirurgie, l’industrie pharmaceutique… les recherches fondamentales et cliniques s’allient

In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting

In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting

In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting

Les actionnaires de SCOR SE sont informés qu'une Assemblée générale ordinaire annuelle et extraordinaire se tiendra le mardi 6 mai 2014 à 10 heures au siège social du groupe SCOR.

SCOR Global Life, a subsidiary of SCOR SE, has entered into a VIF (Value of In-Force) monetization transaction with Mediterráneo Vida, a Spanish insurance company fully owned by Banco Sabadell.